Advertisement

Topics

HARVEY NASH GROUP Company Profile

06:25 EDT 20th September 2018 | BioPortfolio

Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the management broadened the Group’s geographical coverage and increased the range of services, recognising the value this would add to the business in the longer term.

An IPO in April 1997 facilitated a fresh injection of capital into the business, fast tracking expansion into Europe, the USA and Asia. This was achieved through a mix of acquisitions and organic growth.

Today, Harvey Nash holds a unique position as the only truly global IT recruitment business listed on the London Stock Exchange with over 3,000 employees and contractors working across 28 offices worldwide

Location

13 Bruton Street
London
London
W1J 6QA
United Kingdom

Contact

Phone: 44 (0)20 7333 0033
Fax: 44 (0)20 7333 0032
Email: info@harveynash.com


News Articles [939 Associated News Articles listed on BioPortfolio]

Según la encuesta Harvey Nash/KPMG CIO, los directorios de empresas se apresuran a aumentar ...

- Las amenazas de ciberdelitos alcanzan su máximo histórico - Solo un quinto de los líderes de TI del mundo están bien preparados para un Read more...

Harvey Investment Co Has Decreased Its Idex (IEX) Stake; Mangrove...

Harvey Investment Co Llc decreased Idex Corp stake by 9.62% reported in 2017Q4 SEC filing. Harvey Investment Co Llc sold 11,775 shares as Idex Corp 's stock rose 7.15%.

Hurricane Harvey: Dutch-Texan Research Shows Most Fatalities Occurred outside Flood Zones

Harvey, one of the costliest storms in US history, hit southeast Texas on 25 August 2017 causing unprecedented flooding and killing dozens

Data and Cybersecurity Investments Ramp Up as Threats Reach All-Time High

Rajiv LeventhalCompanies are quickly ramping up investment in data and cybersecurity as they look to become more compliant with new data privacy protection and security regulations—and to avoid high...

Wholesome Donates $10,000 to Feeding Texas for ongoing Hurricane Harvey Relief

"We are grateful for the generosity of Wholesome and its customers. Their donation will help our network of food banks continue to nourish Hurricane Harvey Read more...

Unprecedented psychological distress months after Hurricane Harvey

Four months after Hurricane Harvey soaked the Houston area and displaced more than a third of the population, an alarming 52 percent of Harris County residents said they were still struggling to recov...

CM Capital: Mark Harvey shares his views on the best type of scenario for financing a company and why he is optomistic for the future.

In this episode of PharmaTelevision News Review, Fintan Walton talks to Mark Harvey, Partner of CM Capital.

[Comment] FGF-19 agonism for NASH: a short study of a long disease

Non-alcoholic steatohepatitis (NASH) has emerged as the most common cause of liver disease worldwide and is on a trajectory to become the most common indication for liver transplantation.1,2 Interest ...

PubMed Articles [1828 Associated PubMed Articles listed on BioPortfolio]

Nonalcoholic steatohepatitis in posttransplantation liver: Review article.

Nonalcoholic steatohepatitis (NASH) associated or not with cirrhosis is the third leading indication for liver transplantation (LT) around the world. After transplants, NASH has a high prevalence and ...

Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States.

Non-alcoholic steatohepatitis (NASH) is the progressive form of non-alcoholic fatty liver disease (NAFLD). Our aim was to estimate the total economic burden of NASH and advanced NASH in the United Sta...

Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score.

Nonalcoholic steatohepatitis (NASH) is an important etiology of end-stage liver disease. Long-term effect of bariatric surgery in improvement of NASH is not clear.

Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.

Over the past 2 decades, nonalcoholic fatty liver disease (NAFLD) has grown from a relatively unknown disease to the most common cause of CLD in the world. In fact, 25% of the world's population is cu...

Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) can advance, if untreated, to liver fibrosis, cirrhosis, hepatocellular carcinoma, liver failure and liver-related de...

Clinical Trials [4074 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.

It is known that a vast majority of patients seeking a bariatric surgery weight reduction procedure have non-alcoholic fatty liver disease (NAFLD), while a smaller subset of patients withi...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Companies [1668 Associated Companies listed on BioPortfolio]

HARVEY NASH GROUP

Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the m...

Nash Finch Company

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

Harvey & Company LLC

Harvey & Company has a long track record of successful investments and acquisitions across a variety of manufacturing, business service and distribution sectors. Our success is based on the recognitio...

North American Specialty Hospital

Headquartered in Denver, NASH is a US majority-owned and managed enterprise. Incorporating US physicians in its service delivery, NASH is designed to provide pre-operative and pos...

More Information about "HARVEY NASH GROUP" on BioPortfolio

We have published hundreds of HARVEY NASH GROUP news stories on BioPortfolio along with dozens of HARVEY NASH GROUP Clinical Trials and PubMed Articles about HARVEY NASH GROUP for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of HARVEY NASH GROUP Companies in our database. You can also find out about relevant HARVEY NASH GROUP Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record